“`html
Bio-Techne Corp. (TECH) has entered into a distribution agreement with the U.S. Pharmacopeia to sell monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards alongside its analytical solutions, including the Maurice system. This partnership, announced on June 24, aims to enhance monoclonal antibody and gene therapy development globally.
Following the announcement, Bio-Techne’s stock experienced a slight decline of 0.1%, closing at $51.84. The company holds a market capitalization of $8.13 billion and boasts an earnings yield of 3.6%, significantly higher than the industry average of -28.4%. Despite facing development challenges in gene therapy, the new collaboration is expected to boost market sentiment toward BIO-Techne’s stock.
The global monoclonal antibody therapeutics market is valued at $222.6 billion in 2023 and is projected to grow at a compound annual growth rate of 14.5% through 2029, driven by advancements in biotechnology and genetic engineering.
“`
